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ABSTRACT 
Background: 
Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease resulting from 
persistent airflow limitation. The severity of COPD is categorized based on forced expiratory 
volume in one second (FEV1), forced vital capacity (FVC) and the ratio of FEV1/FVC by 
pulmonary function test.  The rate of change in FEV1 could influence COPD management and 
treatment, however, it varies significantly across people. Early disease treatment applied on 
COPD patients with rapid decline in FEV1 could prevent patients from early exacerbation in lung 
function failure.  We hypothesize that plasma biomarkers are associated with COPD progression 
and could identify patients with rapid decline in FEV1. 
Methods: 
A cohort of 313 former smokers was followed for 2 years. Pulmonary function test (for 
FEV1) and computed tomography (for Frac-950 and multiple lobes based on visual emphysema 
score, MLVS) were applied to all subjects when entering the study and at the 2-year follow-up 
visit. Peripheral plasma samples were collected when entering the study and plasma levels of 17 






Plasma levels of C-reactive protein (CRP) and matrix metalloproteinase-1 (MMP1) are 
significant positively associated with continuous FEV1 percent predicted change. Plasma level of 
soluble intercellular adhesion molecule-1 (sICAM1) is significant in estimating continuous Frac-
950 change positively and plasma levels of sICAM1 and MMP1 are significant in estimating 
Frac-950 rapid decline positively. Plasma level of tumor necrosis factor related apoptosis-
inducing ligand (TRAIL) is significant negatively and plasma level of tissue inhibitor of 
metalloproteinases-2 (TIMP2) is significant positively associated with continuous MLVS 
change, and plasma levels of sclerostin (SOST), tissue inhibitor of metalloproteinases-1 (TIMP1) 
and TIMP2 are significant positively associated with MLVS rapid decline. P-values less than 
0.05 are considered significant. 
Conclusions: 
Peripheral plasma biomarkers are associated with COPD progression but variations exist. 
The levels of biomarkers along with baseline lung function could estimate the COPD patients 
with future rapid decline in lung function.  
Public Health Significance: 
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1.0  INTRODUCTION TO COPD 
1.1 DEFINITION OF COPD  
Chronic obstructive pulmonary disease (COPD) is a progressive disease causing 
persistent airflow limitation. It forms primarily due to exposure to noxious particles or gases and 
results in an enhanced chronic inflammatory response in the airways and the lung [1]. 
COPD is caused by a mixture of small airway disease (known as obstructive bronchiolitis) 
and lung parenchymal destruction (known as emphysema) [1]. Obstructive bronchiolitis is a 
result of chronic inflammation which changes the structure by narrowing small airways in lung, 
including lumen collapse, alveolar attachments loss, mucus increase and wall fibrosis [2]. 
Emphysema is defined as permanent destructive enlargement of the airspace distal to the 
terminal bronchiole, affecting both bronchioles and alveoli. Some COPD patients may be 
diagnosed with both obstructive bronchiolitis and emphysema while others only develop one of 
the two disease manifestations [3]. The walls of bronchiole are thickened and the alveoli are 








1.2 ETIOLOGY OF COPD  
1.2.1 Risk factors  
Among the noxious particles and gases, cigarette smoking is the most commonly 
recognized for causing COPD [4, 5]. Approximately 75% of COPD cases are attributed to 
cigarette smoking [6]. The risk of developing COPD and the severity of COPD in smokers 
increase with the amount of cigarette smoked [7].  Persistent smokers (odds ratio (OR) 4.56, 95% 
confidence interval (CI) 2.67~7.79) and restart smokers who quit smoking and restarted (OR 
3.57, 95% CI 1.06~12.00), are more likely to develop COPD than persistent ex-smokers those 
quit and did not restart (OR 1.03, 95% CI 0.58~1.83), compare to non-smokers [8]. Passive 
exposure to cigarette smoke may also contribute to COPD. Exposure to environmental cigarette 
smoke was related to a greater risk of COPD (OR 1.36, 95% CI 1.002-1.84) compared to those 
without the exposure [9].  
In addition to cigarette smoking, other noxious particles from occupational related 
exposures, in-door and out-door air pollution demonstrate significant association with COPD. 
Occupational exposures, such as coal mining, hard-rock mining, concrete-manufacturing etc., 
may account for 15% of COPD cases [10]. Occupational exposure to dusts from agricultural 
industry and mining is associated with increased odds of COPD (OR 1.53, 95% CI 1.17~2.08) 
compared to those not exposed [11]. Indoor and outdoor pollution associated with COPD include 
pollutants from industry, heating, traffic, cooking and other sources. Studies provide evidence of 
association of indoor and outdoor pollution with COPD diagnosis or severity. A positive 
association between exposure to solid fuel and COPD diagnosis has been observed (OR 2.80, 
95% CI 1.85~4.0) [12]. Solid fuel is the solid material for producing energy and providing heat 
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when burning, including wood, coal, peat and pellets made from grains. Higher PM10 (particulate 
matter of less than 10 mm) within 8 km distance from home address was related to an increased 
risk for COPD (OR, 1.33 per 7 mg/m3; 95% CI, 1.03–1.72) [13]. Burning of biomass fuel, 
mainly woody fuel and animal waste, increases development of COPD (OR 1.95, 95% CI 
1.55~2.4) [14].  
Genetic factors are also considered to play an important role in COPD development. The 
most documented genetic risk factor is alpha-1 antitrypsin deficiency, which is a major 
circulating inhibitor of serine proteases [15]. Apha-1 antitrypsin deficiency is most commonly 
seen in individuals of Northern European origin [16]. Although apha-1 antitrypsin deficiency is 
relatively rare, it illustrates the effect of genes on COPD development.  
Besides the inhaled particles and genetic factors, there is evidence of sex differences in 
COPD diagnosis. COPD was considered to be a male dominated disease because men had a 
higher cigarette smoking rate and more exposure to occupational hazards than women.  However, 
the percentage of men versus women diagnosed with COPD is equalizing. Although the age 
adjusted mortality of COPD in men was 1.3 times greater than in women, the absolute death 
numbers of women increased more than that of men, from 58,729 in 1999 to 70,066 in 2009 
compared to an increase from 60,795 in 1999 to 63,899 in 2009 respectively [17]. Potential 
reasons for the increasing cases in women may be a combined effect of increased tobacco 
consumption among women in developed countries, higher risk of exposure to indoor air 
pollution in developing countries, and increased amount of women working in historically male 
dominant jobs which are exposed to occupational dusts [18]. 
Pulmonary function declines during normal aging process. Moreover, cumulative 
exposures to inhaled particles during aging process increase the risk of developing COPD. A 
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systematic review and meta-analysis, including studies from 28 countries between 1990 and 
2004, demonstrate the higher prevalence of COPD in those above 40 years old in comparison 
with those below 40 [19.  
Hu et al studied the effect of nutrition and diet on developing COPD [20]. They found 
that a diet high in antioxidants may be a protective factor in the development of COPD and 
higher plasma vitamin C levels were associated with higher pulmonary function. 
1.2.2 Pathology 
COPD results from persistent inflammation caused by inhaled irritants. The inflammation 
increases the number of inflammatory cells, including neutrophils, lymphocytes and 
macrophages. These inflammatory cells interact with structural cells in the airways and 
parenchyma by breaking down the balance between proteinases and anti-proteinases and the 
balance between oxidative and anti-oxidative and results in COPD [1, 2]. Oxidants and 
proteinases, generated by irritants and derived from inflammatory cells, increase oxidative stress 
and proteinases activity and accelerate inflammation.   
1.3 BURDEN OF COPD 
1.3.1 Prevalence, Mortality and Morbidity 
COPD affects more than 400 million people worldwide, with approximately 65 million 
people have moderate to severe COPD [1, 21]. The burden of disease epidemiology estimates 
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that the average prevalence of moderate or severe COPD is around 10.1% and sex specific rates 
are 11.8% for men and 8.5% for women [22]. In United States, 12.7 million adults over 18 years 
old had COPD in 2011 and an additional 24 million were suspected to have undiagnosed COPD 
[23].  
According to World Health Organization global burden of disease study 2000, COPD 
accounts for 2.75 million deaths worldwide [24]. Chronic lower respiratory disease, primarily 
COPD, was the third leading cause of death in the United States and responsible for 149,205 
deaths in 2011 [25].  
The World Health Organization global burden of disease study states that COPD is the 
fourth leading cause of mortality and will be the third leading cause of mortality worldwide by 
2030 [26]. 
1.3.2 Economic and Social Burden of COPD 
Both direct and indirect costs are high for COPD. In the United States, almost $49.9 
billion was spent on COPD in 2010, including $29.5 billion in direct health care expenditures 
(value of health care for disease diagnosis and medical treatment), $8.0 billion in indirect 
morbidity costs (monetary consequences of disability and missed work) and $12.4 billion in 
indirect mortality costs (productivity lost due to early death) [27]. Worldwide, COPD is the 
twelfth leading cause of DALYs (Disability-Adjusted Life Year) lost in the world, responsible 
for 2.1% of the total in 1990. COPD is projected to be the seventh leading cause of DALYs lost 
by 2030 [28].  
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1.4 COMORBIDITIES OF COPD 
COPD is a complex syndrome often developed in middle age along with diseases related 
to aging [29]. There is growing recognition that inflammation of COPD not only affect lung but 
also is harmful to non-pulmonary organs.  
Patients with COPD have a higher prevalence of osteoporosis compared to health adults 
(32.5% versus 11.4% respectively, p-value<0.001) [30-34]. Bone mineral density value 
decreases as the severity of COPD and decrease in pulmonary function associates with 
osteoporosis (OR=0.46, p-value=0.04) [35]. Bone attenuation positively correlates with 
pulmonary function (r=0.06, p-value=0.01) and negatively correlates with extent of emphysema 
(r=-0.09, p-value<0.001) [36].  Osteoporosis is disease with increased bone fragility due to 
decreased bone density. Besides common risk factors, aging and smoking, COPD influences on 
vitamin D level. A group of 44 males with COPD show 27% of them have lower serum 
concentration of 25 hydroxyvitamin D (25(OH) vitamin D) compared to the lower limit of that 
for healthy subjects [37].  The treatment for COPD can also influence osteoporosis. Oral 
corticosteroid, a medicine for COPD, is associated with higher rate of non-vertebral fracture 
(relative rate (RR) =1.33, 95% CI 1.29-1.38), hip fracture (RR=1.61, 95% CI 1.47-1.76) and 
vertebral fracture (RR=2.60, 95% CI 2.31-2.92) [38].  
The prevalence of skeletal muscle weakness is shown to be higher in COPD patients 
(32.3% versus 8.0%, p-value<0.05) and higher prevalence rate is reported in severe COPD cases 
(OR 2.2, 95% CI 1.3-3.7) [39]. The prevalence of obesity or being overweight was increased in 
COPD patients than in those without airflow limitation in a population based sample (29.4% 
versus 24.3%; and 44.7% versus 43.0%, respectively; p-values<0.05) [40]. COPD patients tend 
to have a higher risk for cognitive impairment (36% versus 12%, p-value=0.007) and dementia 
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(42% versus 14%, p-value<0.05) [41, 42]. A nationwide population-based study estimates that 
the overall incidence rate of Parkinson’s disease is 57% higher in the COPD patients than in non-
COPD controls [43]. The pulmonary and cardiovascular systems are intimately related [44]. 
Evidence shows COPD patients have increased arterial stiffness which could be measured by 
pulse wave velocity (pulse wave velocity 11.4 m/s in COPD patients versus 8.95 m/s in healthy 
subjects, p-value<0.0001) [45]. Patients with COPD have higher risk of developing coronary 
artery disease (OR 2.0, 95% CI 1.5-2.5), angina (OR 2.1, 95% CI 1.6-2.7), myocardial infarction 
(OR 2.2, 95% CI 1.7-2.8), stroke (OR 1.5, 95% CI 1.1-2.1), and congestive heart failure (OR 3.9, 
95% CI 2.8-5.5) [46]. Those associations are seen worldwide [47-61].   
Comorbidities with COPD are common. A review on COPD comorbidities shows 97.7% 
patients have one or more comorbidities and 53.5% patients with four or more comorbidities 
[62]. Up to 25% of the population 65 years and older with COPD has two comorbid conditions 
and up to 17% have three [63]. On average, COPD patients aged 65 years and older have three or 
more chronic conditions [64]. The increasing number of comorbidities decreases quality of life 
(r=0.45 with poor quality of life, p-value<0.05) and self-reported health status [65, 66]. The 
comorbidities of COPD may contribute to increased morbidity and mortality [67, 68], and are 
positively associated with increased exacerbations and hospitalizations [69-74]. Anant RC Patel 
and John R Hurst’s research reported that more patients with COPD may die from comorbidities 
of COPD than they do from COPD itself [75].  
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1.5 CLINICAL PHENOTYPING OF COPD  
1.5.1 Spirometry 
Clinical diagnosis of COPD is determined based on spirometry testing. Spirometry is the 
most common pulmonary function test measuring lung function, specifically the amount and/or 
speed of air that can be inhaled and exhaled. When it is used to confirm COPD diagnosis, it is 
generally carried out with pre- and post-bronchodilator usage, a medication to open up the 
airways [76]. Two main components are recorded: the greatest volume of air that can be exhaled 
in a single deep breath (forced vital capacity, FVC) and the greatest volume of air that can be 
exhaled in the first second of a breath (forced expiratory volume in one second, FEV1) [77].  The 
ratio of these two measurements is calculated (FEV1/FVC).  
The values of FEV1 and FVC depend on age, sex, height and ethnicity. In healthy adults, 
the ratio of FEV1 to FVC is approximately 0.75~0.80, while in patients with obstructive disease, 
FEV1 is diminished because of increased airway resistance to expiratory flow resulted from the 
premature closure of airway in expiration [78]. Although both FEV1 and FVC are reduced in 
COPD, FEV1 is affected more because of the increased airway resistance.  A post-bronchodilator 
FEV1/FVC <0.70 indicates that the patient has a persistent airflow limitation and is the 
diagnostic criteria for COPD [1].  
The global initiative for obstructive lung disease (GOLD) divide COPD into four stages 






Table 1 Spirometric Classification of COPD Severity Based on Post-Bronchodilator FEV1 
Mild 
FEV1/FVC <0.70 
FEV1 pp*>=80% predicted 
Moderate 
FEV1/FVC<0.70 
50%<= FEV1 pp <80% predicted 
Severe 
FEV1/FVC<0.70 
30%<= FEV1 pp <50% predicted 
Very Severe 
FEV1/FVC<0.70 
FEV1 pp <30% predicted  
* FEV1 pp (FEV1 percent predicted) is the FEV1 of the patient divided by the average FEV1 in the 
population for any person of similar age, sex, height and ethnicity [79]. 
1.5.2 Quantitative computed tomography (CT) measurement and semi-
quantitative CT measurement 
 Traditional pulmonary function test, spirometry, is a measurement of airway dominant 
COPD and has a low sensitivity in diagnosing early stage of emphysema [80]. Around 30% of 
patients may develop emphysema before exhibiting detectable decline in a spirometry pulmonary 
function test [81]. There are two measurements for emphysema, one is quantitative CT and the 
other is semi-quantitative visual assessment based on CT image.   
Computed tomography (CT) is an imaging procedure to describe inner body by X-ray. 
High-resolution CT scans have been proven to reflect microscopic emphysema [82]. Software 
calculates the emphysema index as the fraction of voxels less than −950 Houndsfield Unit (Frac-
950) as a percent of total voxels identified as lung regions similar to the traditional density mask 
[83].   
Multiple lobes based visual emphysema score system (MLVS) is a new system to score 
the degree of emphysema in the lung based on the CT image. It is an improvement of traditional 
used visual emphysema score and is based on a visual inspection of the CT image by 
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professional radiologist. To derive the MLVS, the left and right lung are divided into 6 segments 
with upper, middle and lower regions of the right lung and the upper, lingula and lower regions 
of the left lung. The upper and lower segments in each side of lung are assigned with weight 2 
respectively, and middle and lingula segments with weight 1 respectively. The visual 
emphysema score of each segment is multiplied by the weight for that segment. Then sum of all 
segment-specific visual scores are then divided by 10 (the sum of weights) to derive the final 
MLVS value. 
Although Frac-950 and MLVS were two ways of measuring emphysema, they do have 
differences.  MLVS is calculated by professional radiologist while Frac-950 is derived 
automatically by computational methods. Sometimes, Frac-950 and MLVS score provide 
different information for the same patient. Radiologist may miss some of the emphysematous 
changes if the changes are too small and may rate a small MLVS score. Similary, structural 
abnormality may also lead an inaccurate rating of emphysema in the computation of Frac-950 
score. 
Frac-950 and MLVS are continuous variables. Higher values of Frac-950 and MLVS 
indicate more severe COPD.  
1.6 DISEASE PROGRESSION IN COPD 
A key feature of COPD is the accelerated decline in FEV1. However, the rate of change 
in FEV1 varies significantly. A study by Vestbo shows the mean rate of change in FEV1 is a 
decline of 33 ml/year with a 59 ml/year standard deviation [84]. In addition, 38% of the study 
participants had an estimated rate of change of decline in FEV1 by more than 40 ml per year, 
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31% declined by 21 to 40 ml per year, 23% declined 20 ml/year to increased 20 ml/year and 8% 
increased more than 20 ml/year (Figure1 [84]).  
 
 
“Reproduced with permission from (scientific reference citation), Copyright Massachusetts Medical Society. 
Figure 1. Distribution of Estimated Annual Rates of Change in FEV1 over a 3-Year Period in 
Patients with COPD 
 
Knowing the predicted rate of change in FEV1 could influence disease management and 
treatment.  This could prevent early exacerbations in lung function failure, especially for the 
rapid decliners.  Therefore, identifying patients with rapid decline in FEV1 is important and 
urgent for COPD treatment. 
1.7 PLASMA BIOMARKERS   
Biomarkers may provide novel strategies for selecting patients with high risk of rapid 
decline in FEV1.  Biomarkers may reflect disease progression [85]. Common sample sources of 
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biomarkers for COPD include exhaled breath, induced sputum, bronchoalveolar lavage fluid, 
lung biopsies, and peripheral blood. However, the first four measurements are invasive of the 
procedures, have poor reproducibility, and a lack of standardization of measurements. These 
methodological deficiencies limit their clinical application [86]. The focus of biomarker 
discovery has been regarding blood specimens as they are reliable, cost-effective and readily 
available in clinical settings [87]. 
Existing research indicates certain blood-based biomarkers are related to lung function 
and clinical outcomes such as exacerbations, morbidity and mortality [88]. Peripheral 
biomarkers associated with COPD clinical phenotype, disease severity and development have 
been reported including C-reactive protein (CRP), fibrinogen, surfactant protein D (SPD) and 
Clara cell protein (CCP) [89-94]. Increases in plasma level of CRP overtime are associated with 
decreases in FEV1 % predicted [91]. Higher levels of fibrinogen are associated with COPD 
exacerbations and severe airflow limitation [92]. Elevated plasma levels of SPD were observed 
in COPD compared to controls [93].  
As discussed in the pathology section, inflammation is a process including inflammatory 
cells and cytokines. Research shows that matrix metalloproteinase-12 (MMP12) degrades the 
extracellular matrix (ECM), for example elastin, and matrix metalloproteinase-9 (MMP9) 
degrades serine protease inhibitor, alpha-1 antiproteinase, during inflammation. Tissue Inhibitor 
of Metalloproteinases (TIMPs) inhibits the function of MMPs. Fluctuation in TIMPs affects 
MMPs. SPD and CCP are known lung specific protein involved in inflammation. CRP, Serum 
amyloid A (SAA) and human pentraxin-related protein 3 (hPTX3) belong to acute phase protein, 
a class of protein whose plasma concentration increase or decrease in response to inflammation. 
Soluble Intercellular Adhesion Molecule-1 (sICAM1) and Soluble Vascular cell Adhesion 
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Molecule-1 (sVCAM1) are two cell adhesion molecules that bind with ECM in cell adhesion 
process and activate or damage cell and endothelium.  Tumor Necrosis Factor Receptor Type I 
(TNFRI), Tumor Necrosis Factor Receptor Type II (TNFRII) and TNF-Related Apoptosis-
Inducing Ligand (TRAIL) are related to tumor necrosis factors (TNF) and apoptosis, which 
regulate the pathway implicated in resolution of inflammatory processes. Soluble Fas Receptor 
(sFas) is a protein and leads to cell death.  Studies have demonstrated that TRAIL and sFas 
initiate inflammation besides the role as initiators of apoptosis [95]. Sclerostin (SOST), a 
glycoprotein, is associated with osteoporosis by anti-anabolic effects on bone formation. 
Osteoporosis and emphysema are epidemiologically associated disease of cigarette smoking. The 
finding that antigen-specific autoimmune response, anti-GRP 78 autoantibodies, are associated 
with osteoporosis and emphysema indicates SOST, proven to associated with osteoporosis, may 
associated with COPD inflammation [96]. Table 2 shows a list of the selected biomarkers we 















Table 2. Description of 17 Plasma Biomarkers  
Biomarker Full Name Abbreviation Function 
Matrix metalloproteinase-1  MMP1 proteinase related to inflammation 
Matrix metalloproteinase-7  MMP7 proteinase related to inflammation 
Tissue Inhibitor of Metalloproteinases-1 TIMP1 proteinase related to inflammation 
Tissue Inhibitor of Metalloproteinases-2 TIMP2 proteinase related to inflammation 
Tissue Inhibitor of Metalloproteinases-4 TIMP4 proteinase related to inflammation 
Clara Cell Protein CCP  lung-specific protein 
Surfactant Protein D SPD  lung-specific protein 
C-Reactive Protein CRP  inflammatory  protein  
Serum Amyloid A  SAA  inflammatory  protein  
Human Pentraxin-related Protein 3 hPTX3  inflammatory  protein  
Soluble Intercellular Adhesion Molecule-1 sICAM1  inflammatory  protein  
Soluble Vascular cell Adhesion Molecule-1  sVCAM1  inflammatory  protein  
Tumor Necrosis Factor Receptor Type I  TNFRI induces apoptosis 
 Tumor Necrosis Factor Receptor Type II  TNFRII induces apoptosis 
TNF-Related Apoptosis-Inducing Ligand  TRAIL  induces apoptosis 
Soluble Fas Receptor sFas  inhibits apoptosis 





2.0  RATIONALE AND HYPOTHESIS 
Former studies show the variation of COPD progression by FEV1 and identify plasma 
biomarkers’ association with COPD inflammation. However, few longitudinal studies of patient 
cohorts have provided the association between peripheral plasma biomarker and COPD 
progression. Therefore, we observe the three clinical phenotypes of COPD, FEV1, Frac-950 and 
MLVS, on a group of former smokers. We believe that peripheral plasma level of biomarkers at 
beginning of the study could affect the change in clinical phenotypes of COPD and can estimate 
2-year COPD progression. 
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3.0  STUDY DESIGN AND EXPERIMENTAL METHODS 
3.1 STUDY POPULATION 
Subjects were recruited from the existing Pittsburgh Specialized Center in Clinically 
Oriented Research (SCCOR) cohort. The SCCOR study focuses on advanced cellular and 
molecular investigations of lung tissue changes involved in COPD to increase understanding of 
disease progression. The subjects from the Pittsburgh SCCOR cohort consisted of former 
smokers with more than 10 pack-years smoked, who are older than 40 years old and without 
significant non-COPD related comorbidities at baseline.  
Data collection for the baseline visit was conducted between July 2007 and November 
2012. The 2-year follow-up visits were conducted at 2 years after the initial baseline visit, from 
July 2009 to November 2014. Institutional Review Board of the University of Pittsburgh 
approved this study. 
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3.2 CLINICAL PHENOTYPES AND DATA COLLECTION 
3.2.1 Pulmonary Function Test 
All participants performed standardized spirometry according to the European 
Respiratory Society guidelines, recording FEV1 at baseline and at the 2-year follow-up visit. 
FEV1 percent predicted (FEV1 pp) value is calculated by dividing the individual’s FEV1 by the 
average FEV1 in the population for any person of similar age, sex, height and ethnicity [79]. 
Smaller values of FEV1 pp indicate more severe COPD. The continuous change of FEV1 pp 
between first and second measurements for every participant was calculated by subtracting the 
baseline value from the 2-year follow-up value. A positive value of FEV1 pp change indicates an 
improvement where COPD gets better. Based on clinical experience, we define an FEV1 rapid 
decline if FEV1 pp decreases by at least 5%. 
3.2.2 Quantitative and semi-quantitative CT measurement  
Each participant completed two chest CT scans, one at baseline and the other at the 2-
year follow-up visit. Frac-950 was recorded for every participant for each visit. Greater values of 
Frac-950 indicates severe emphysema. The change in Frac-950 between baseline and 2-year 
follow-up for every participant was calculated by subtracting the baseline value from the 2-year 
follow-up value. An increase in continuous change in Frac-950 implies disease exacerbation. 




MLVS was calculated for every participant by professional technician for each visit. 
Greater value of MLVS indicates severe emphysema. The change in MLVS between baseline 
and 2-year follow-up for every participant was calculated by subtracting the baseline value from 
the 2-year follow-up value. An increase in continuous change in MLVS implies disease 
exacerbation. Based on clinical experience, we define a MLVS rapid decline if MLVS increases 
by at least 0.5. 
3.3 PLASMA BIOMARKERS 
Plasma biomarkers samples were collected using citrated blood from subjects at baseline 
and banked at -80ºC. A total of 18 plasma biomarkers (shown in Table 2) were analyzed. 
TRAIL, sFas, SOST, TNFRI, TNFRII, CRP, SAA, sICAM1, sVCAM1 were analyzed using 
MSD multiplex assays (Meso Scale Discovery); MMP1, MMP7, TIMP1, TIMP2, TIMP4 were 
analyzed using Performance Assay. MMP and TIMP were analyzed using multi-plex Kits (R and 
D Systems) on a Luminex system, CCP and SPD were measured using ELISA (Biovendor R and 
D) and hTSP1 and hPTX3 were measured using ELISA duo set (R and D Systems). All of the 
assays were performed according to the manufacture’s instruction. Analysis were performed in 
duplicates (ELISAs) or at least 15% of the samples on each assay plate were performed in 
duplicates (MSD and Luminex). Coefficient of variation was controlled at <15%. 
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3.4 STATISTICAL ANALYSIS 
Continuous data were summarized as mean ± standard deviation and categorical data 
were summarized with percentages. Log-transform was applied to all biomarkers. P-values less 
than 0.05 are considered statistically significant. 
3.4.1 Continuous Clinical Measurements 
Univariate linear regression analysis was used to determine the associations of individual 
biomarker and the continuous changes of FEV1 pp, Frac-950 and MLVS respectively. 
Multivariable regression analysis was used to determine the associations of individual plasma 
biomarkers with the continuous changes of FEV1 pp, Frac-950, and MLVS, adjusting for age, 
sex, smoking status and baseline measurements of FEV1 pp, Frac-950 and MLVS, respectively.  
Stepwise selection method was used for variable selection and Akaike Information Criterion 
(AIC) for comparing models and choosing the optimal model. 
3.4.2 Binary Clinical Measurements 
Logistic regression analysis was applied to estimate the associations of plasma 
biomarkers with the rapid decline of FEV1 pp, Frac-950, and MLVS with and without adjusting 
for age, sex, smoking status and baseline measurements of FEV1 pp, Frac-950 and MLVS, 
respectively.  Stepwise selection method was used for variable selection and Akaike Information 
Criterion (AIC) for comparing models and choosing the optimal model. 
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3.4.3 Influential Observations 
In this study, the influential observations include the observations those do not fit the 
current model and those whose removal cause a large change to the model fit.  
All statistical procedures were performed with R (version i386 3.1.1). 
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4.0  RESULTS 
4.1 SUBJECT CLINICAL AND DEMOGRAPHIC CHARACTERISTICS 
The 2-year follow-up cohort consisted of 313 subjects, including 118 (37.70%) current 
smokers and 162 (51.76%) males. The mean age was 68 (± 6.09) years, ranging from 42 to 85 
years old. FEV1 pp ranged from 23% to 133% with a mean 85.44% (± 21.47). Frac-950 ranged 
from 0.001 to 0.38 with a mean of 0.04 (± 0.07). MLVS ranged from 0 to 5 with a mean of 0.95 
(± 1.29) (Table 3). 
 
Table 3. Subject Characteristics at Baseline 
 (N=313) 
Characteristic Mean ± SD or n (%) 
Age 68 ± 6.09 
Males 162(51.76%) 
Current Smoker 118(37.70%) 
FEV1 pp 85.44 ± 21.47 
Frac-950 0.04 ± 0.07 
MLVS 0.95  ± 1.29 
 
Distribution of continuous changes in FEV1 pp, Frac-950 and MLVS are shown in Figure 









Histogram of Continuous FEV1 pp 








































Table 4. Summary for Rapid Decline of FEV1, Frac-950 and MLVS 
  FEV1  rapid decline 
Frac-950 
 rapid decline 
MLVS  
rapid decline 
Yes 92(29.39%) 71(22.68%) 57(18.21%) 
No  221(70.61%) 242(77.32%) 256(81.79%) 
4.2 PERIPHERAL BLOOD BIOMARKERS 
All plasma levels of biomarkers are log-transformed for ease of calculation and 
comparison. Baseline levels are summarized in Table 5. 
 
Table 5. Summary for Plasma Level of Biomarkers at Baseline 
Characteristic (Log-Transform) Mean ± SD 
TRAIL (pg/ml) 4.44 ± 0.38 
sFas (pg/ml) 8.96 ± 0.32 
SOST (pg/ml) 4.02 ± 0.51 
TNFRI (pg/ml) 7.09 ± 0.30 
TNFRII (pg/ml) 7.88 ± 0.33 
CRP (pg/ml) 14.00 ± 1.25 
SAA (pg/ml) 14.73 ± 0.96 
sICAM1 (pg/ml) 12.09 ± 0.42 
sVCAM1 (pg/ml) 12.45 ± 0.41 
MMP1 (pg/ml) 7.65 ± 0.81 
MMP7 (pg/ml) 9.27 ± 0.50 
TIMP1 (pg/ml) 11.11 ± 0.25 
TIMP2 (pg/ml) 11.12 ± 0.20 
TIMP4 (pg/ml) 7.14 ± 0.40 
CCP (ng/ml) 1.43 ± 0.61 
SPD (ng/ml) 4.40 ± 0.55 
hPTX3 (pg/ml) 6.19 ± 0.61 
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4.3 ASSOCIATION BETWEEN CHANGE IN FEV1 PP AND PLASMA 
BIOMARKERS 
4.3.1 Continuous FEV1 pp change 
Table 6 contains the unadjusted and adjusted results of regressing each biomarker 
individually on FEV1 pp change over 2 years. Plasma levels of CRP and MMP1 are statistically 
significant and positively associated with continuous FEV1 pp change when adjusting for age, 
sex, smoking status and FEV1 pp value when entering the study. With 1 pg/ml increases in the 
log-transformed plasma level of CRP, the estimated change in FEV1 pp increases by 0.87 with 
adjusting for age, sex, smoking status and FEV1 pp at baseline. Plasma level of TIMP1 shows a 
positive trend in estimating FEV1 pp change with adjustment (regression coefficient=2.95, p-
value=0.07). 
Using the stepwise selection method, the plasma levels of TNFRI, TNFRII, CRP, MMP1 
and SPD, together with age, sex, smoking status and FEV1 pp value when entering in study, best 
estimated the FEV1 pp change among the 17 available plasma biomarkers (Table 7). 12.07 % of 
variance in continuous FEV1 pp change could be explained by age, sex, smoking status, baseline 
value of FEV1 pp and plasma levels of TNFRI, TNFRII, CRP, MMP1 and SPD. 3.40% of 
variance in continuous FEV1 pp change could be explained by the selected plasma level of 
biomarkers (the R-square for estimating FEV1 pp change by adjustments only is 8.67%). Plasma 
levels of CRP and MMP1 are positively associated with FEV1 pp change (regression 
coefficient=0.85 and 1.08, p-value=0.01 and 0.03, respectively). The higher plasma level of CRP 
at baseline, the greater the estimated value of FEV1 pp change. FEV1 pp at baseline is highly 
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significantly associated with continuous FEV1 pp change (regression coefficient=11.73, p-
value<0.001). 
 




Coefficient P-value Coefficient P-value 
TRAIL  0.56 0.60 -0.001 0.99 
sFas  1.04 0.43 0.17 0.90 
SOST  -0.07 0.94 -0.45 0.58 
TNFRI  1.50 0.29 1.44 0.29 
TNFRII  0.46 0.71 0.33 0.79 
CRP  0.55 0.10 0.87 0.007 
SAA  0.53 0.22 0.58 0.17 
sICAM1  -0.02 0.98 0.17 0.86 
sVCAM1  -0.35 0.73 -0.13 0.89 
MMP1  0.86 0.09 1.15 0.02 
MMP7  -0.50 0.55 -0.49 0.56 
TIMP1  2.52 0.13 2.95 0.07 
TIMP2  0.72 0.73 0.71 0.73 
TIMP4  -1.29 0.21 -0.80 0.45 
CCP  1.02 0.14 0.44 0.55 
SPD  0.54 0.48 0.94 0.20 
hPTX3  -0.65 0.34 -0.57 0.39 
 *Adjusted for age, sex, smoking status and FEV1 pp at baseline. 
 
Table 7. Fitted Model for Estimating Continuous FEV1 pp Change 
Dependent Variable Independent Variable* Coef. P-value AIC R-Squared MSE 
FEV1 pp Change 
TNFRI 4.09 0.15 
1218.76 0.12 46.06 
TNFRII -0.99 0.11 
CRP 0.85 0.01 
MMP1 1.08 0.03 
SPD 1.09 0.14 
Age -0.11 0.11 
Male -0.31 0.69 
Smoking(Y) -0.94 0.25 
FEV1 pp at baseline 11.73 <0.001 
*Log-transform applied to plasma level of biomarkers. 
26 
 
There are some observations could influence the selection of plasma biomarkers (solid 
red points shown in Figure 3). After removing these observations, the plasma level of MMP1 is 
no longer significant in estimating FEV1 pp change in the fitted model (regression 
coefficient=0.57, p-value=0.19), and plasma level of CRP and FEV1 pp at baseline are still 
significant positively in estimating FEV1 pp change (regression coefficient=0.73 and 13.52, p-
value=0.01 and <0.001, respectively).  
 
Figure 3. Residual Plot of Fitted Model for Continuous FEV1 pp Change 
 

















4.3.2 FEV1 rapid decline 
Table 8 contains the unadjusted and adjusted results of regressing each biomarker 
individually on FEV1 rapid decline over 2 years. When estimating the association between FEV1 
rapid decline and biomarkers one at a time, there are no significant associations observed. 
Plasma level of CCP shows a trend in association with FEV1 pp change without adjustment 
(OR=0.69, p-value=0.06), however, this trend does not show up after adjusting for age, sex, 
smoking status and FEV1 pp at baseline (OR=0.82, p-value=0.38). 
 




Odds Ratio P-value Odds Ratio P-value 
TRAIL  0.85 0.63 0.95 0.89 
sFas  0.75 0.46 0.96 0.92 
SOST  0.85 0.52 0.95 0.85 
TNFRI  0.68 0.36 0.62 0.30 
TNFRII  0.86 0.68 0.85 0.69 
CRP  0.94 0.52 0.85 0.12 
SAA  0.89 0.37 0.87 0.32 
sICAM1  0.92 0.77 0.84 0.57 
sVCAM1  1.24 0.47 1.19 0.59 
MMP1  0.91 0.56 0.83 0.25 
MMP7  1.08 0.76 1.01 0.96 
TIMP1  0.68 0.43 0.58 0.30 
TIMP2  1.66 0.41 1.89 0.34 
TIMP4  1.29 0.40 1.11 0.77 
CCP  0.69 0.06 0.82 0.38 
SPD  1.00 0.98 0.89 0.63 
hPTX3  1.13 0.55 1.12 0.59 
 *Adjusted for age, sex, smoking status and FEV1 pp at baseline. 
 
According to stepwise selection method, the plasma levels of CRP, sICAM1 and 
sVCAM1, together with age, sex, smoking status and FEV1 pp at baseline, could best estimate 
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the FEV1 pp change among the 17 available plasma biomarkers (Table 9). Only plasma level of 
sVCAM1 shows a positive trend in estimating FEV1 rapid decline among the selected 3 
biomarkers (OR=2.78, p-value=0.07). The association between FEV1 pp at baseline and FEV1 
rapid decline is significant and for one unit increase in FEV1 pp at baseline, the odds of rapid 
decline in FEV1 (versus no rapid decline) would decrease by 95.76% while holding age, sex, 
smoking status and plasma levels of the three biomarkers remain the same.  
 
Table 9. Fitted Model for Estimating FEV1 Rapid Decline 
Dependent Variable Independent Variable* Odds Ratio P-value AIC 
 FEV1 Rapid Decline 
CRP 0.84 0.14 
362.15 
sICAM1 0.44 0.16 
sVCAM1 2.78 0.07 
Age 1.02 0.44 
Male 1.00 0.99 
Smoking(Y) 1.64 0.08 
FEV1 pp at baseline 0.04 <0.001 
               *Log-transform applied to plasma level of biomarkers. 
 
The ROC curve for the fitted model shows a moderate fit and the area under the curve is 
69.53% (Figure 4). Based on the fitted model for FEV1 rapid decline, the observed and predicted 
values are shown in Table 10. The fitted model has a high specificity, 93.21%, however, the 
sensitivity is low, 20.65%.  
 
Table 10. Contingence Table of FEV1 Rapid Decline 
Predicted FEV1 
Rapid Decline 
Observed FEV1  
Rapid Decline Validation Measurement 
Decline No Decline Classification Rate Sensitivity Specificity 
Decline 19 15 71.88% 20.65% 93.21% 





























4.4 ASSOCIATION BETWEEN CHANGE IN QUANTITATIVE MEASUREMENT 
OF EMPHYSEMA AND PLASMA BIOMARKERS 
4.4.1 Continuous Frac-950 change 
Table 11 contains the unadjusted and adjusted results of regressing each biomarker 
individually on Frac-950 change over 2 years. Plasma level of sICAM1 is positively associated 
with continuous Frac-950 change when adjusting for age, sex, smoking status and Frac-950 at 
baseline (regression coefficient=0.004, p-value=0.02). When keeping age, sex, smoking status 
and Frac-950 at baseline constant, 1 pg/ml increase in log-transformed plasma level of sICAM1 
increases the continuous Frac-950 change by 0.004. Plasma level of TRAIL, SOST, sVCAM1 
and SPD show a positive trend in estimating Frac-950 change with adjustment.  
According to stepwise selection method, the plasma levels of TRAIL, sICAM1, TIMP2, 
CCP and SPD, together with age, sex, smoking status and Frac-950 at baseline, could best 
estimate the continuous Frac-950 change among the 17 available plasma biomarkers (Table 12). 
21.56% of variance in continuous Frac-950 change could be explained by age, sex, smoking 
status, Frac-950 at baseline and plasma levels of TRAIL, sICAM1, TIMP2, CCP and SPD. 2.54% 
of variance in continuous Frac-950 change could be explained by the selected plasma level of 
biomarkers (the R-square for estimating Frac-950 change by adjustments only is 0.19). Plasma 
level of sICAM1 is positively associated with Frac-950 change (regression coefficient=0.004, p-
value=0.02). The higher plasma level of sICAM1 at baseline, the greater the estimated value of 
Frac-950 change. Plasma level of TRAIL shows a positive trend in estimating Frac-950 change 
(regression coefficient=0.004, p-value=0.09). Frac-950 at baseline is highly significantly 









Coefficient P-value Coefficient P-value 
TRAIL  0.001 0.59 0.004 0.07 
sFas  -0.002 0.46 0.001 0.75 
SOST  -0.001 0.92 0.001 0.40 
TNFRI  0.004 0.18 0.005 0.06 
TNFRII  0.003 0.28 0.004 0.13 
CRP  0.001 0.48 0.001 0.39 
SAA  0.0003 0.72 0.001 0.41 
sICAM1  0.003 0.15 0.004 0.02 
sVCAM1  0.003 0.18 0.003 0.09 
MMP1  0.002 0.09 0.001 0.20 
MMP7  -0.001 0.79 0.002 0.36 
TIMP1  -0.0003 0.93 0.001 0.88 
TIMP2  -0.005 0.21 -0.004 0.34 
TIMP4  -0.0004 0.87 -0.0001 0.94 
CCP  0.002 0.21 0.002 0.12 
SPD  0.003 0.11 0.002 0.10 
hPTX3  0.001 0.40 0.002 0.19 
             *adjusted for age, sex, smoking status and Frac-950 at baseline. 
 
Table 12. Fitted Model for Estimating Continuous Frac-950 Change 
Dependent Variable Independent Variable* Coef. P-value AIC R-Squared MSE 
Frac-950 Change 
TRAIL 0.004 0.09 
-2696.17 0.22 0.0002 
sICAM1 0.004 0.02 
TIMP2 -0.006 0.14 
CCP 0.002 0.15 
SPD 0.002 0.16 
Age 0.0001 0.54 
Male 0.0004 0.78 
Smoking(Y) -0.0003 0.86 
frac-950 at baseline 0.11 <0.001 




There are some observations influencing the magnitude of plasma biomarkers (solid red 
points shown in Figure 5). After removing these observations, the positive trend between plasma 
level of TRAIL is no longer significant in the fitted model, and plasma level of sICAM1 and 
Frac-950 at baseline change are significantly positive in estimating Frac-950 change (regression 
coefficient=0.002 and 0.14, p-value=0.04 and <0.001 respectively).  
 
Figure 5. Residual Plot of Fitted Model for Continuous Frac-950 Change 
 
















4.4.2 Frac-950 rapid decline 
Table 13 contains the unadjusted and adjusted results of regressing each biomarker 
individually on Frac-950 rapid decline over 2 years. Plasma level of MMP1 is significant 
positively associated with Frac-950 rapid decline with and without adjusting for age, sex, 
smoking status and Frac-950 at baseline (OR=1.60 and 1.67, p-value=0.01 and 0.003, 
respectively. Table 13). For 1 pg/ml increase in log-transformed plasma level of MMP1 at 
baseline, the odds of Frac-950 rapid decline increase by 59.52% and 66.94% with and without 
adjustment respectively. There is a negative trend between plasma level of TRAIL and Frac-950 
rapid decline without adjustment (OR=0.53, p-value=0.07) but this trend is not observed after 
adjustment (OR=0.92, p-value=0.83). 
According to stepwise selection method, the plasma levels of sICAM1, sVCAM1, MMP1 
and TIMP2, together with age, sex, smoking status and Frac-950 at baseline, could best estimate 
Frac-950 rapid decline among the 17 available plasma biomarkers (Table 14). Plasma levels of 
sICAM1 and MMP1 are significantly positively associated with Frac-950 rapid decline among 
the four selected plasma biomarkers (OR=4.46 and 1.59, p-value=0.02 and 0.02, respectively). 
















Odds Ratio P-value Odds Ratio P-value 
TRAIL  0.53 0.07 0.92 0.83 
sFas  0.56 0.18 0.65 0.39 
SOST  0.67 0.12 0.89 0.71 
TNFRI  1.60 0.30 1.55 0.39 
TNFRII  1.44 0.37 1.39 0.46 
CRP  1.17 0.15 1.25 0.09 
SAA  1.03 0.83 1.15 0.38 
sICAM1  1.10 0.77 1.61 0.19 
sVCAM1  0.94 0.86 1.00 0.99 
MMP1  1.67 0.003 1.60 0.01 
MMP7  1.09 0.76 1.54 0.19 
TIMP1  1.61 0.38 1.54 0.47 
TIMP2  0.59 0.45 0.36 0.20 
TIMP4  1.03 0.93 0.93 0.85 
CCP  1.28 0.29 1.13 0.67 
SPD  1.41 0.17 1.47 0.19 
hPTX3  1.24 0.33 1.33 0.24 
             *Adjusted for age, sex, smoking status and Frac-950 at baseline. 
 
Table 14. Fitted Model for Estimating Frac-950 Rapid Decline 
Dependent Variable Independent Variable* Odds Ratio P-value AIC 
Frac-950 Rapid Decline 
sICAM1 4.46 0.02 
238.28 
sVCAM1 0.29 0.07 
MMP1 1.59 0.02 
TIMP2 0.28 0.12 
Age 1.07 0.009 
Male 1.73 0.09 
Smoking(Y) 0.68 0.26 
Frac-950 at baseline 6453931.26 <0.001 




The ROC curve for the fitted model shows a moderate fit and the area under the curve is 
83.81% (Figure 6). Based on the fitted model for Frac-950 rapid decline, the observed and 
predicted values are shown in Table 15. The fitted model for Frac-950 rapid decline has a high 
specificity but a low sensitivity (specificity=95.45% and sensitivity=23.94%).  
Table 15. Contingence Table of Frac-950 Rapid Decline 
Frac-950 Rapid 
Decline 
Frac-950 Rapid Decline Validation Measurement 
Decline No Decline Classification Rate Sensitivity Specificity 
Decline 17 11 79.23% 23.94% 95.45% 
No Decline 54 231 
 
 






















4.4.3 Continuous MLVS change 
Table 16 contains the unadjusted and adjusted results of regressing each biomarker 
individually on MLVS change over 2 years. Plasma levels of TRAIL, SOST and sICAM1 are 
significant negatively associated with continuous MLVS change (all regression coefficient<0 and 
all p-values<0.05), while plasma level of TIMP2 is positively associated with continuous MLVS 
change (regression coefficient=0.30 and 0.32, p-value=0.02 and 0.03, respectively), with and 
without adjusting for age, sex, smoking status and MLVS at baseline. Plasma level of sVCAM1 
shows a negative trend in estimating MLVS change with and without adjustment (regression 
coefficient=-0.11 and -0.14, p-value=0.06 and 0.05, respectively), and plasma level of TIMP4 
show a positive trend in estimating MLVS change without adjustment (regression 
coefficient=0.13, p-value=0.08). 
According to stepwise selection method, the plasma levels of TRAIL, sFas, SOST, 
sICAM1, TIMP1, TIMP2 and TIMP4, together with age, sex, smoking status and MLVS at 
baseline, could best estimate the continuous MLVS change among the 17 available plasma 
biomarkers (Table 17). 35.3% of variance in continuous Frac-950 change could be explained by 
age, sex, smoking status, MLVS at baseline and plasma levels of TRAIL, sFas, SOST, sICAM1, 
TIMP1, TIMP2 and TIMP4. 4.8% of variance in continuous MLVS change could be explained 
by the selected plasma level of biomarkers. Only plasma levels of TRAIL and TIMP2 of the 
selected plasma level of biomarkers are significantly associated with MLVS change with 
opposite direction (regression coefficient=-0.15 and 0.34, p-value=0.03 and 0.02, respectively). 
The lower plasma level of TRAIL at baseline, the greater the estimated value of MLVS change. 
While the higher plasma level of TIMP2 at baseline, the greater the estimated value of MLVS 
change. Plasma levels of sICAM1 and TIMP1show negative trends in estimating MLVS change 
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while plasma level of Fas shows a positive trend (regression coefficient=-0.13, -0.23 and 0.1527, 
p-value=0.07, 0.05 and 0.06, respectively). MLVS at baseline is significant positively associate 
with continuous MLVS change (regression coefficient=0.22, p-value<0.001). 
 




Coefficient P-value Coefficient P-value 
TRAIL  -0.27 <0.001 -0.15 0.03 
sFas  0.03 0.75 0.11 0.16 
SOST  -0.25 <0.001 -0.15 0.003 
TNFRI  0.06 0.56 0.06 0.51 
TNFRII  0.06 0.53 0.04 0.57 
CRP  -0.01 0.74 -0.02 0.23 
SAA  -0.03 0.39 -0.03 0.28 
sICAM1  -0.20 0.005 -0.18 0.003 
sVCAM1  -0.14 0.05 -0.11 0.06 
MMP1  0.03 0.48 -0.02 0.58 
MMP7  -0.05 0.45 -0.04 0.45 
TIMP1  -0.05 0.68 -0.08 0.46 
TIMP2  0.32 0.03 0.30 0.02 
TIMP4  0.13 0.08 0.07 0.29 
CCP  0.05 0.31 0.04 0.32 
SPD  -0.01 0.89 -0.05 0.31 
hPTX3  -0.01 0.78 -0.03 0.49 
 *Adjusted for age, sex, smoking status and MLVS at baseline. 
 
There are some observations could influent the significance of plasma biomarkers (solid 
red points shown in Figure 7). After removing these observations, the plasma level of TRAIL is 
no longer significant in estimating MLVS change in the fitted model (regression coefficient=-
0.06, p-value=0.23), the plasma levels of SOST and TIMP1 become significant in estimating 
MLVS change in the fitted model (regression coefficient=-0.09 and -0.18, p-value=0.04 and 
0.0465, respectively),  and plasma level of TIMP2 and MLVS at baseline are still significant 
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positively in estimating MLVS change in the fitted model (regression coefficient=0.33 and 0.17, 
p-value=0.004 and <0.001, respectively).  
 
Table 17. Fitted Model for Estimating Continuous MLVS Change 
Dependent Variable Independent Variable* Coef. P-value AIC R-Squared MSE 
MLVS Change 
TRAIL -0.15 0.03 
-521.74 0.35 0.18 
sFas 0.15 0.06 
SOST -0.09 0.14 
sICAM1 -0.13 0.07 
TIMP1 -0.23 0.05 
TIMP2 0.34 0.02 
TIMP4 0.11 0.11 
Age 0.0004 0.92 
Male -0.01 0.78 
Smoking(Y) 0.06 0.26 
MLVS at baseline 0.22 <0.001 
















Figure 7. Residual Plot of Fitted Model for MLVS Change 
 
4.4.4 MLVS rapid decline 
Table 18 contains the unadjusted and adjusted results of regressing each biomarker 
individually on MLVS rapid decline over 2 years. Plasma levels of TRAIL, SOST and sICAM1 
is significant negatively associated with MLVS rapid decline (all OR<1, all p-value<0.05) while 
plasma level of TIMP2 is significant positively associated with MLVS rapid decline with and 
without adjusting for age, sex, smoking status and MLVS at baseline (OR=8.81 and 4.12, p-













value=0.03 and 0.04, respectively. Table 18). There is a negative trend between plasma level of 
sVCAM1 and MLVS rapid decline with and without adjustment (OR=0.41 and 0.51, p-
value=0.05 and 0.06, respectively). 
 




Odds Ratio P-value Odds Ratio P-value 
TRAIL  0.27 0.001 0.34 0.04 
sFas  0.96 0.92 2.35 0.18 
SOST  0.27 <0.001 0.30 0.001 
TNFRI  0.84 0.72 0.64 0.50 
TNFRII  1.06 0.89 0.97 0.95 
CRP  0.96 0.71 0.85 0.32 
SAA  0.83 0.23 0.67 0.06 
sICAM1  0.40 0.009 0.28 0.006 
sVCAM1  0.51 0.06 0.41 0.05 
MMP1  1.04 0.81 0.83 0.40 
MMP7  0.70 0.23 0.53 0.13 
TIMP1  0.63 0.42 0.44 0.28 
TIMP2  4.12 0.04 8.81 0.03 
TIMP4  1.50 0.26 0.91 0.85 
CCP  1.17 0.53 1.09 0.81 
SPD  1.17 0.56 0.91 0.83 
hPTX3  1.07 0.77 1.04 0.91 
            *Adjusted for age, sex, smoking status and MLVS at baseline. 
 
According to stepwise selection method, plasma levels of TRAIL, sFas, SOST, TIMP1, 
and TIMP2, together with age, sex, smoking status and MLVS at baseline, could best estimate 
MLVS rapid decline among the 17 available plasma biomarkers (Table 19). Plasma levels of 
SOST and TIMP1 are significant negatively (OR=0.33 and 0.12, p-value=0.005 and 0.03, 
respectively), and plasma level of TIMP2 and MLVS at baseline are significant positively in 
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estimating MLVS rapid decline in the fitted model (OR=25.74 and 4.32, p-value=0.01 and 
<0.001, respectively). 
 
Table 19. Fitted Model in Estimating MLVS Rapid Decline 
Dependent Variable Independent Variable* Odds Ratio P-value AIC 
MLVS Rapid Decline 
TRAIL 0.33 0.07 
173.83 
sFas 4.00 0.05 
SOST 0.33 0.005 
TIMP1 0.12 0.03 
TIMP2 25.74 0.009 
Age 1.04 0.33 
Male 0.62 0.28 
Smoking(Y) 1.84 0.19 
MLVS at baseline 4.32 <0.001 
             *Log-transform applied to plasma level of biomarkers. 
 
The ROC curve for the fitted model shows a good fit and the area under the curve is 
93.49% (Figure 8). Based on the fitted model for MLVS rapid decline, the observed and 
predicted values are shown in Table 20. The fitted model has a high specificity and a moderate 
sensitivity in estimating MLVS rapid decline (specificity=96.88% and sensitivity=61.40%). 
 
Table 20. Contingence Table of MLVS Rapid Decline 
MLVS Rapid 
Decline 
MLVS Rapid Decline Validation Measurement 
Decline No Decline Classification Rate Sensitivity Specificity 
Decline 35 8 90.42% 61.40% 96.88% 

































5.0  DISCUSSION 
COPD is a progressive disease affecting a large population. During the past decade, the 
mortality of COPD has continued to increase. Due to the key feature of COPD that accelerated 
decline in FEV1, early treatment to the rapid lung function decliners will reduce disease burden 
and disease exacerbation for patients.  
In this study, we identified and selected the plasma biomarkers in estimating both 
continuous change and rapid decline in FEV1, Frac-950 and MLVS. Table 21, 22 and 23 are 
summaries for selected plasma biomarkers in estimating pulmonary measurements.  
We find there are common plasma biomarkers in estimating different phenotype of 
COPD progression and the associations are consistent between different phenotypes. A higher 
plasma level of sVCAM1 indicates a greater FEV1 rapid decline while a lower level indicates a 
greater Frac-950 rapid decline. A lower plasma level of sICAM1 indicates a greater FEV1 rapid 
decline while a higher level indicates a greater Frac-950 rapid decline. These results are seem to 
be contradicted. They are consistent in actual since higher FEV1 and lower Frac-950 indicate a 
healthier lung.  
We also find there are common plasma biomarkers with inconsistent association between 
phenotypes. Higher plasma level of SPD indicates both greater continuous change in FEV1 pp 
and Frac-950. Higher plasma level of MMP1 indicates greater FEV1 pp change and greater Frac-
950 rapid decline.  
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Frac-950 and MLVS are two measurements for emphysema. For the same plasma 
biomarker, it should have a consistent relationship with these two measurements. However, it is 
not always the case. We observe higher plasma level of sICAM1 associates with greater 
continuous change and a greater rapid decline in Frac-950 while lower value associates with 
greater MLVS change. Similar association is observed for plasma level of TRAIL.  
We observed there were biomarkers consistently in estimating COPD progression within 
the same phenotype. Plasma level of sICAM1 is positively associated with both continuous 
change and rapid decline in Frac-950, and plasma levels of TRAIL, SOST and TIMP1 are 
negatively while plasma levels of sFas and TIMP2 are positively associated with both continuous 
change and rapid decline in MLVS. We also observed there was inconsistent relationship within 
the same phenotype. Higher levels of CRP indicate greater FEV1 pp change while lower levels 
indicate greater FEV1 rapid decline. This contradiction may due to the cut-off point chosen for 
FEV1 rapid decline. Besides, we noticed the selected plasma biomarkers were almost the same in 
estimating MLVS change and rapid decline.  
 
Table 21. Significant association between FEV1 and biomarkers 
Biomarker 
(log-transform) 
Continuous  FEV1 pp Change   FEV1 Rapid Decline 
Unadjusted Adjusted* Fitted Model Unadjusted Adjusted* Fitted Model 
TNFRI (+) (+) (+)       
TNFRII (+) (+) (-)       
CRP (+) (+) (+) (-) (-) (-) 
MMP1 (+) (+) (+)       
SPD (+) (+) (+)       
sICAM1       (-) (-) (-) 
sVCAM1       (+) (+) (+) 
*Adjusted for age, sex, smoking status and FEV1 pp at baseline. (+)/(-) signs show positive/negative association and 





Table 22. Significant association between Frac-950 and biomarkers 
Biomarker 
(log-transform) 
Continuous Frac-950 Change   Frac-950 Rapid Decline 
Unadjusted Adjusted* Fitted Model Unadjusted Adjusted* Fitted Model 
TRAIL (+) (+) (+)       
sICAM1 (+)       (+) (+) (+) (+) (+) 
TIMP2 (-) (-) (-) (-) (-) (-) 
CCP (+) (+) (+)       
SPD (+) (+) (+)       
sVCAM1       (-) (+) (-) 
MMP1       (+) (+) (+) 
*Adjusted for age, sex, smoking status and Frac-950 at baseline. (+)/(-) signs show positive/negative association and 
significant ones are marked in red and italics.  
 
Table 23. Significant association between MLVS and biomarkers 
Biomarker 
(log-transform) 
Continuous  MLVS Change MLVS Rapid Decline 
Unadjusted Adjusted* Fitted Model Unadjusted Adjusted* Fitted Model 
TRAIL (-) (-) (-) (-) (-) (-) 
sFas (+) (+) (+) (-) (+) (+) 
SOST (-) (-) (-) (-) (-) (-) 
sICAM1 (-) (-) (-)       
TIMP1 (-) (-) (-) (-) (-) (-) 
TIMP2 (+) (+) (+) (+) (+) (+) 
TIMP4 (+) (+) (+)       
*Adjusted for age, sex, smoking status and MLVS at baseline. (+)/(-) signs show positive/negative association and 
significant ones are marked in red and italics.  
 
We find that plasma levels of TIMP1 and TIMP2 have opposite association with 
continuous change and rapid decline in MLVS. Although TIMP1 and TIMP2 come from the 
same family, tissue inhibitor of metalloproteinase, they render based on different protein and 
have different function. Besides inhibiting matrix metalloproteinases, TIMP2 could suppress the 
proliferation of endothelial cells. Endothelium involve in inflammation [97]. Therefore, plasma 




We find the baseline values of FEV1 pp, Frac-950 and MLVS play an active and 
important role in estimating their corresponding change or rapid decline. The R-squares by 
baseline values are much greater than the R-squares by selected plasma biomarkers. 
We noticed that the plasma biomarkers selected to estimate FEV1 were almost different 
from those selected to estimate Frac-950 and MLVS. The biomarkers for estimating FEV1 may 
more related to small airway disease while the biomarkers for Frac-950 and MLVS are related to 
parenchymal destruction. 
Our results are consistent with existing published results of associations between plasma 
biomarkers and inflammation. Plasma level of TRAIL is significantly higher in COPD patients 
compared to healthy group (50.17±17.70 versus 42.09±15.49 pg/ml, p-value=0.03) [98]. 
Enhanced level of MMP1 is observed in gingival inflammation [99]. Increased sFas levels are 
associated with pulmonary fibrosis and bronchiolitis [100, 101]. Serum level of ICAM1 is 
elevated in vascular inflammation [102] Decreased TIMP1 levels are associated with COPD 
exacerbation (from 3.5 microg/g to 1.5 microg/g, p<0.05) [103]. Low concentrations of CCP are 
associated with accelerated FEV1 decline (4.4 mL/year additional FEV1 decline, p=0·0014) 
[104].  
However, we also have contradictory results with existing literature. Elevated level of 
CRP is associated with increased COPD hospitalization and death (hazard ratio=1.4 and 2.2) 
[105]. Serum level of VCAM1 is elevated in vascular inflammation [104]. Higher levels of 
TNFRI is associated with ventilator-associated pneumonia (regression coefficient=8.9, p-
value=0.01) [106]. High circulating SOST indicates a greater risk of osteoporosis-related 
fractures (p-value<0.001) which has a higher prevalence in COPD patients [35, 107]. High 
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concentrations of CRP are associated with accelerated FEV1 decline (30 mL/year additional 
FEV1 decline, p<0·001) [108]. Further study is needed to discuss the inconsistence.  
This study has two strengths. The plasma biomarkers are selected based on pathology of 
COPD, including lung specific proteins, inflammatory protein and proteinase, and apoptosis 
related cytokines. These selected biomarkers are proven to be directly or indirectly associated 
with inflammation. In addition, we considered biomarker related to COPD comorbidity, 
osteoporosis.  
There are limitations in this study. COPD is a disease with systematic inflammation, 
involving many plasma biomarkers. In this study, only 17 biomarkers’ relationships with COPD 
progression are discussed. The selected biomarkers to predict COPD progression from the 
available 17 biomarkers could only explain a small portion of variation. Identifying more plasma 
biomarkers associated with COPD will make the progression prediction more accurate. In 
addition, the measurements may have noise. Our 2-year follow up study only measured twice 
which may be inaccurate or insufficient in measuring COPD progression, making association 
and variable selection vary.  
Identify the COPD patients with rapid decline in different COPD phenotypes based on 
more robust models by correctly defining the rapid decline in COPD phenotypes and including 
more biomarkers and repeated measurements in the future study could improve the accuracy on 




6.0  PUBLIC HEALTH IMPACT 
COPD is a systemic disease with manifestations affecting lungs and extra-pulmonary 
organs.  COPD and its comorbidities increase hospitalizations, morbidity and mortality, and 
adversely impacts quality of life. Identifying patients who will have a rapid decline in lung 
function prior to the decline is necessary to provide aggressive treatment to the appropriate 
patients.  Plasma biomarkers, which are inexpensive and easily obtained, could be used to 
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